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Paclitaxel (Taxol) is a novel chemotherapeutic drug that is effective against breast and ovarian cancers.
Although the primary target of paclitaxel is microtubules, its efficacy exceeds that of conventional microtubule-
disrupting agents, suggesting that it may have additional cellular effects. Previously, we demonstrated that
paclitaxel can induce interleukin-8 (IL-8) gene expression at the transcriptional level in subsets of human
ovarian cancer lines. In this as well as the previous report, we present evidence that this ability is not linked
to the lipopolysaccharide pathway of IL-8 gene induction. The present study identifies the cis-acting elements
and trans-acting factors involved in this induction by transfecting DNA constructs containing the 5*-flanking
region of the IL-8 gene linked to the chloramphenicol acetyltransferase reporter gene into paclitaxel-responsive
and nonresponsive ovarian cancer cells (responsiveness refers to the IL-8 response). Paclitaxel only activated
the IL-8 promoter in responsive cells. The AP-1 and NF-kB binding sites in the IL-8 promoter are required for
activation by paclitaxel; in contrast, a C/EBP site required for IL-8 promoter activation in other cell types is
not involved. Gel shift assays demonstrate that paclitaxel causes a marked increase in protein binding to the
NF-kB and AP-1 consensus binding sequences in the paclitaxel-responsive ovarian cells, but not the nonre-
sponsive cells. The induction of NF-kB and AP-1 binding is reduced by the addition of protein kinase C
inhibitors and cyclic AMP effector, respectively. These results demonstrate a molecular mechanism for cell-
specific paclitaxel-induced IL-8 gene expression which may have clinical relevance.
Paclitaxel is a novel antineoplastic drug which has shown
promise in the treatment of previously unresponsive breast,
ovary, lung, and colon cancers. Paclitaxel is active at nanomo-
lar concentrations and functions by binding to the amino-ter-
minal region of the b-tubulin molecule, thereby promoting and
stabilizing the formation of microtubules. However, the ther-
apeutic effectiveness of paclitaxel exceeds that of microtubule-
disrupting agents such as colchicine and vinca alkaloids, sug-
gesting that paclitaxel may have multiple effects on cells.
Recent studies in mice show that paclitaxel and bacterial lipo-
polysaccharide (LPS) can induce a broad range of shared bio-
activities in macrophages, which includes the following: (i)
induction of a series of cytokines, such as interleukin-1a (IL-
1a), IL-1b, tumor necrosis factor alpha (TNF-a), and IP-10 (1,
5, 15, 36–38); (ii) internalization of TNF-a receptors (14, 15);
(iii) induction of a panel of immediate early genes; (iv) provi-
sion of a second signal for macrophage tumoricidal activity and
nitric oxide production (25); and (v) induction of the phos-
phorylation of mitogen-activated protein kinases and activa-
tion of the autophosphorylation of lyn kinase (15, 22, 36, 37).
In addition, LPS-hyporesponsive C3H/HeJ mice do not re-
spond to paclitaxel with the same pattern of phosphorylation
and gene induction as other mice do, suggesting that paclitaxel
and LPS may share a functionally important signaling trans-
duction pathway (15, 37).
In contrast to its effect on mouse cells, the effect of paclitaxel
on human macrophages/monocytes has been more difficult to
demonstrate. However, paclitaxel activates IL-8 but not IL-1a
or IL-1b or IL-6 transcription in a subset of human ovarian
cancer cell lines and in freshly explanted ovarian cancer cells
(32). Since ovarian cancer represents a primary type of tumor
that is clinically responsive to paclitaxel, these findings may
have significant clinical ramifications.
IL-8 is a member of the superfamily of C-X-C chemokines
(29), and it is a chemotactic factor for T cells, neutrophils, and
basophils (41, 47, 59). IL-8 induction in tumors may be bene-
ficial to the host in that immune cells are attracted to the tumor
site. In fact a recent study by Hirose et al. shows that this is
indeed the case (23). Alternatively, IL-8 also enhances angio-
genesis and may enhance metastasis (51). Regardless of which
role IL-8 plays in a clinical setting, understanding how pacli-
taxel activates the IL-8 gene can elucidate additional molecular
targets of paclitaxel and provide an understanding which may
lead to better antitumor therapies.
The IL-8 gene is regulated at both the transcriptional and
posttranscriptional levels. The former is primarily mediated by
multiple cis elements, including a CCAAT box, a steroid-re-
sponsive element, an HNF-1 element, two IRF-1 elements, an
AP-1 sequence, an AP-3 site, a C/EBP sequence, and an NF-
kB–NF-IL-6 overlapping sequence (30, 40, 42, 46). Earlier, we
demonstrated that paclitaxel can induce IL-8 gene expression
in human ovarian cancer cells at the transcriptional level, as
determined by nuclear run-on assays (32). In the present study,
we investigated the molecular mechanisms responsible for the
tumor-specific induction of the IL-8 gene by paclitaxel. The
study shows that paclitaxel induces a series of activation steps
that lead to IL-8 synthesis; this activation cascade is highly cell
specific and is found only in a subset of ovarian carcinoma
cells.
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Cells and reagents. The human ovarian cancer cell lines OVCA 420 (a gift
from Robert Bast, Jr., M. D. Anderson, Houston, Tex.) and OVCA 194 (a gift
from Oto Martinez-Maza, University of California at Los Angeles, Los Angeles)
were maintained as monolayer cultures in DMEM/F12 medium supplemented
with 5% fetal bovine serum. The derivation of these cells has been described
previously (49). Cells were seeded in 100-mm-diameter plates (Falcon Inc.,
Plymouth, England) and grown in DMEM supplemented with 5% fetal bovine
serum until they reached 60 to 75% of confluence. Immediately before use, the
medium was removed and the cells were washed once with sterile phosphate-
buffered saline and then treated with paclitaxel or the vehicle, dimethyl sulfoxide
(DMSO). Stock paclitaxel was stored at 270°C at a concentration of 30 mM. The
final concentration of DMSO never exceeded 0.1%. Paclitaxel was stored at 4°C
and warmed to room temperature just prior to use.
Plasmid constructs. The plasmids pUXCAT-546, pUXCAT-133, pUXCAT-
98, and pUXCAT-85 were as described previously (42). Additional mutant chlor-
amphenicol acetyltransferase (CAT) plasmids were generated by inserting the
corresponding double-stranded oligonucleotides into pUXCAT-133. Briefly,
pUXCAT-133mAP-1 contains a mutated AP-1 binding site, which was generated
by oligonucleotide site-directed mutagenesis (changing the AP-1 site from
TGACTCA to TATCTCA) using 2133 IL8CAT as the wild-type template.
pUXCAT-133mNF-kB contains a mutated NF-kB site with GGAATTTCCT
changed to TAACTTTCCT. pUXCATmC/EBP contains a mutated C/EBP site
with CAGTTGCAAATCGT changed to AGCTTGCAAATCGT (57). Plasmid
pUXCAT3XHLAkB contains three tandem repeats of the NF-kB binding site
from positions 2189 to 2177 of the HLA-B7 gene (46). Plasmid
pUXLUC2X(2126/2120) contains two copies of the IL-8 AP-1 binding site
(TGACTCA) from the IL-8 promoter (45) inserted upstream of the IL-8 en-
hancer-less core promoter (250 to 144 bp) linked to a firefly luciferase gene.
Plasmid pUXLUC3XColAP-1 contains three copies of the AP-1 binding site
from the collagenase promoter linked to the luciferase reporter gene. The con-
struction of the remaining plasmids within the pUXCAT series has been re-
ported elsewhere (42). Briefly, the sequences from 294 to 280 and from 280 to
271 of IL-8 were synthesized in triplicate and then were inserted into 250CAT
to create pUXCAT3X(294/280) and pUXCAT3X(280/271), respectively.
Plasmid mut MEKK was obtained from Channing J. Der (University of North
Carolina).
Transfection and CAT assay. Cells from the human ovarian cancer cell lines
OVCA 420 and OVCA 194 were transfected by the calcium phosphate method
(8). Four hours after transfection, the cultures were glycerol shocked and re-
plenished with fresh medium. Trypsin was added after 2 to 3 h to release the
cells. These cultures were subdivided and plated into two 100-mm-diameter
dishes (3 3 106 cells per dish), which were incubated overnight at 37°C and 5%
CO2. The cultures were then treated with DMSO or paclitaxel for 24 h prior to
extract preparation. CAT enzymatic activity was assayed as described elsewhere
(44, 46). To address variations in transfection efficiency, each construct was
tested with at least two separate plasmid preparations in three independent
experiments. These multiple experiments should have eliminated experiment-to-
experiment variations in transfection efficiency.
Nuclear extract preparation and EMSA. Nuclear extracts from OVCA 420
cells were prepared as previously described (13) by using a modification of
Dignam’s procedure (13). Electrophoretic mobility shift assays (EMSAs) were
performed as described previously (24, 56). Four to six micrograms of nuclear
extracts was incubated with 2 mg of poly(dI-dC) and 50,000 to 100,000 cpm of
32P-end-labeled DNA probe in a 20-ml reaction volume. After incubation for 20
min at room temperature, the complex was subjected to electrophoresis in a 6%
nondenaturing polyacrylamide gel containing 13 Tris-glycine.
Oligonucleotides. The IL-8 NF-kB binding site was created by annealing the
oligonucleotide 59-ATCGTGGAATTTCCTCTGACA-39 to its complementing
strand. Other binding sites were as follows (point mutations are underlined):
IL-8 mutant NF-kB (mNF-kB), 59-ATCGTTAACTTTCCTCTGACA-39; IL-8
C/EBP, 59-CATCAGTTGCAAATCGTGGA-39; IL-8 mutant C/EBP (mC/EBP),
59-CATAGCTTGCAAATCGTGGA-39; IL-8 AP-1, 59-AGTGTGATGACT
CAGGTTTG-39; IL-8 mutant AP-1 (mAP-1), 59-AGTGTGATATCTCAGG
TTTG-39 (45).
Antibodies. Anti-p65 and anti-p50 antisera were obtained from Albert Baldwin
(Lineberger Cancer Center, University of North Carolina at Chapel Hill). The
anti-p65 antiserum was raised against a C-terminal peptide (LLSGDEDFSSI
ADMDFSALLSQISS) of NF-kB. Anti-p50 antibody was raised against an N-
terminal peptide of the p50 subunit. The polyclonal immunoglobulin Gs against
Sp1, p52, and c-Jun were obtained from Santa Cruz Biotechnology, Inc. (Santa
Cruz, Calif.).
EMSA supershift. The nuclear extract for antibody supershift was prepared
according to the method of Dignam et al. (13) from OVCA 420 cells grown in
100-mm-diameter plates to a density of 2 3 106. Briefly, the cells were resus-
pended in a volume of buffer A (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl,
and 0.5 mM dithiothreitol [DTT]) five times the volume of the packed cells and
then stored on ice for 10 min. The cells were spun down at 209 3 g in a
microcentrifuge at 4°C for 10 min, and the pellet was resuspended in twice the
volume of buffer A and homogenized by 10 strokes with a Dounce homogenizer.
The nuclear pellets were resuspended in buffer C (20 mM HEPES, 20% glycerol,
0.6 M KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl
fluoride [PMSF], and 0.5 mM DTT) followed by 10 strokes with the Dounce
homogenizer. The clear supernatants were obtained by centrifugation at maxi-
mum speed (14,300 3 g) in a microcentrifuge for 30 min. The supernatants were
dialyzed in buffer D (20 mM HEPES, 20% glycerol, 100 mM KCl, 0.2 mM
EDTA, 0.5 mM PMSF, and 0.5 mM DTT) for at least 5 h. Antibody supershift
experiments were performed by preincubating 1 mg of antibody for 2 h on ice
with each binding reaction mixture prior to the addition of the DNA probe.
Northern blot. Total RNA was isolated from paclitaxel- and DMSO-treated
cell lines by the guanidinium isothiocyanate-CsCl method as described previously
(9). Three to five micrograms of purified RNA were loaded into each lane of a
denaturing agarose gel (50). IL-8 and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) cDNA probes were hybridized to Northern blots as described
previously (52).
IL-8 ELISA. IL-8 was measured as previously described (32). Briefly, a goat
anti-human IL-8 antibody (R&D, Minneapolis, Minn.) was used as the coating
antibody, rabbit polyclonal anti-human IL-8 antiserum (Endogen) was used as
the primary antibody, and alkaline phosphatase-conjugated goat anti-rabbit an-
tibody (Capel) was used as the secondary reagent (10). The enzyme-linked
immunosorbent assay (ELISA) is sensitive at the range of nanograms per milli-
liter.
RESULTS
A sequence spanning positions 2133 to 144 of the IL-8 gene
promoter is sufficient to mediate activation by paclitaxel. A
previous report from our group showed that paclitaxel induces
IL-8 secretion in a subset of human ovarian cancer cells, with
the OVCA 420 and OVCA 429 cell lines as prime examples of
paclitaxel-responsive cell lines and OVCA 194 and OVCA 494
as examples of nonresponsive lines. Nuclear run-on assays in-
dicate that paclitaxel selectively induces the expression of the
IL-8 gene at the transcriptional level (32). IL-8 induction in
human ovarian cancers is likely distinct from the cytokine (e.g.,
IL-1 and TNF-a) induction by paclitaxel observed in murine
macrophages (1, 5, 15, 36–38). For the latter, the induction is
tightly linked to the LPS response. Murine macrophages de-
fective in LPS response do not activate cytokine genes in re-
sponse to paclitaxel. In human tumor cells, we have previously
shown that a colon carcinoma line which is defective in LPS
responsiveness nonetheless produced IL-8 when incubated
with paclitaxel (32). Evidence for the converse is now pre-
sented in this report, where OVCA 194, which does not pro-
duce IL-8 in response to paclitaxel, can respond to LPS treat-
ment with IL-8 synthesis (Table 1). These results clearly show
a dichotomy in the LPS and paclitaxel responses with respect
to IL-8 induction.
To delineate the mechanism by which paclitaxel induces
IL-8 gene transcription, paclitaxel-responsive promoter ele-
ments in the IL-8 promoter were identified in this study. This
was done by transfecting OVCA 420 cells with plasmid con-
structs containing the CAT reporter gene driven by the wild
type and deletion mutants of the IL-8 promoter (Fig. 1A).
Twenty-four hours posttransfection, cells were stimulated with
DMSO (the diluent for paclitaxel) or paclitaxel. The full-length
promoter was reproducibly activated by paclitaxel. Deletion of
sequences upstream of position 2133 decreased the constitu-
tive promoter activity but had little effect on paclitaxel induc-
TABLE 1. LPS-induced IL-8 secretion in paclitaxel-nonresponsive
OVCA 194 cells
Treatmenta Amt IL-8 (ng/ml)b
LPS 1 ng/ml 8.07
Paclitaxel 30 mM 0.37
DMSOc 0.43
a Cells were treated for 6 h.
b Measured by ELISA.
c Concentration never exceeded 0.1%.
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ibility (Fig. 1B). In contrast, deletion of sequences upstream of
298 significantly reduced inducibility by paclitaxel, and dele-
tion of sequences upstream of 285 abolished all induction.
This maps the region from 2133 to 285 as a paclitaxel-respon-
sive region which is likely to contain individual paclitaxel-re-
sponsive regulatory elements.
To identify the cis-acting elements in the 2133 to 285 re-
gion of the IL-8 promoter which served as a paclitaxel-respon-
sive regulatory element, site-directed mutant constructs were
prepared and tested. The results shown in Fig. 1B indicate that
mutation in the AP-1 (pUXCAT-133mAP-1) or the NF-kB site
(pUXCAT-133mNF-kB) resulted in a significant reduction of
inducibility by paclitaxel. The C/EBP site was shown to act
cooperatively with NF-kB to induce IL-8 gene transcription in
response to IL-1, TNF, and tetradecanoyl phorbol acetate
(TPA) (42). Mutation of this C/EBP site (pUXCAT-133mC/
EBP) had no effect on paclitaxel-induced CAT activity. These
results indicate that the AP-1 and NF-kB binding sites of the
IL-8 promoter are specifically important for induction by pa-
clitaxel in OVCA 420 cells.
The various IL-8 promoter constructs were also tested in the
paclitaxel-nonresponsive OVCA 194 cell line (32). The results
demonstrate that paclitaxel had no effect on either the full-
length 2546 or the 2133 deletion construct (Fig. 2). This lack
of effect on the IL-8 promoters in OVCA 194 cells correlates
precisely with the lack of IL-8 chemokine induction in this cell
line (32). This analysis was extended to the OVCA 429 cell
line, which also responds to paclitaxel with IL-8 synthesis, and
the nonresponsive OVCA 494 cell line as previously reported
(32). As shown in Table 2, paclitaxel induced the IL-8 pro-
moter in the OVCA 429 line but not the OVCA 494 line. This
indicates that IL-8 cytokine induction by paclitaxel is reflected
at the promoter level and that IL-8 promoter analysis in pa-
clitaxel-responsive versus paclitaxel-nonresponsive lines is use-
ful in elucidating the underlying mechanism of tumor-specific,
paclitaxel-activated gene expression.
AP-1 and NF-kB sites of the IL-8 gene are sufficient to
mediate paclitaxel-induced gene activation. The IL-8 gene
fragment spanning positions 2133 to 144 contains three
prominent DNA-protein interaction sites for the transcription
FIG. 1. Sequences within 2133 to 285 kb of the IL-8 promoter are necessary for activation by paclitaxel. (A) Potential binding sites for transcription factors present
in the region are indicated by the various shaded boxes. Deletion constructs were cloned into the pUXCAT plasmid (open box) as shown. Also, several mutant DNAs
(pUXCAT-133mAP-1, pUXCAT-133mC/EBP and pUXCAT-133mNF-kB) were synthesized by oligonucleotide site-directed mutagenesis and then inserted into
2133pUXCAT as described in Materials and Methods. (B) After transfection with the appropriate plasmids, the OVCA 420 cells were treated with DMSO or 30 mM
paclitaxel (Taxol) as indicated for 24 h. Cell extracts were prepared and CAT assays were performed as described in Materials and Methods. These results represent
the averages of three independent experiments. Error bars indicate standard errors.
FIG. 2. Nonresponsive OVCA 194 cells did not show significant induction of
CAT activity by paclitaxel (Taxol) treatment for any of the constructs shown in
Fig. 1. The results were compiled from three independent experiments. Error
bars indicate standard errors.
TABLE 2. Paclitaxel activation of the IL-8 promotera in four
ovarian carcinoma cell lines







a pUXCAT-133 used for transfection.
b Fold induction of paclitaxel-treated cells normalized to CAT activity of
DMSO-treated cells. Results represent averages of three experiments.
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factors AP-1, C/EBP, and NF-kB. To further determine which
sites are sufficient for activation by paclitaxel, several con-
structs were used (Fig. 3A). Each construct contains three
tandemly repeated copies of one of the following elements: the
NF-kB site from the IL-8 gene, the C/EBP site from the IL-8
gene, the NF-kB site from the HLA-B7 gene, or two copies of
the AP-1 binding site from the IL-8 gene. Each was linked to
the minimal IL-8 promoter spanning 250 to 144 bp and to the
CAT reporter gene. All constructs were tested in the pacli-
taxel-responsive OVCA 420 and the nonresponsive OVCA 194
cells.
The construct pUXCAT3X(280/271), which contains three
tandem repeats of the NF-kB sites from the IL-8 gene, gener-
ated an eightfold stimulation by paclitaxel. In contrast, colchi-
cine treatment of OVCA 420 cells resulted in only a slight
increase in expression (Fig. 3B). A construct that contains
three copies of the NF-kB site from the human HLA B-7 gene
was marginally activated by treatment with paclitaxel and col-
chicine (Fig. 3B and C). This indicates that the kB sequence in
the IL-8 promoter is preferred for paclitaxel induction. The
induction of pUXCAT3X(280/271) is cell-specific because
paclitaxel did not activate this construct in OVCA 194 cells.
Again, colchicine treatment of OVCA 194 produced a small
increase in CAT expression which approximates that observed
in OVCA 420 cells (compare Fig. 3B and C). This indicates
that the colchicine effect is not cell line-specific while the
paclitaxel effect is cell line-specific. Construct pUXCAT3X
(294/280), which contains three copies of the C/EBP site from
the IL-8 gene, did not exhibit paclitaxel inducibility in either
OVCA 420 or OVCA 194 cells.
A construct, pUXLUC2X(2126/2120), which contains two
tandemly repeated copies of the AP-1 element derived from
the IL-8 gene linked to the luciferase reporter gene, was also
introduced into OVCA 420 and OVCA 194 cells. As shown in
Fig. 3B and C, paclitaxel treatment enhanced luciferase activity
in OVCA 420 cells by 5.5-fold but it did not activate this
construct in OVCA 194 cells. As a positive control, phorbitol
myristate acetate (PMA), which is known to activate the AP-1
transcription factor, was transfected into the cells, and it en-
hanced luciferase expression by sevenfold in both OVCA 420
and OVCA 194 cells (Fig. 3B and C). A second construct,
pUXLUC3XColAP-1, which contains three copies of the AP-1
binding site from the collagenase promoter, was also selec-
tively activated in OVCA 420 but not OVCA 194. Another
positive control, an activated form of MEKK (mut MEKK)
known to activate the AP-1 transcription factor, was trans-
fected into cells, and it enhanced luciferase expression by 35-
fold in both OVCA 420 and OVCA 194 cells (Fig. 3B and C).
This indicates that AP-1 can be equally activated in both cell
lines by PMA and MEKK, but the cell lines exhibit differential
responses to paclitaxel. These results demonstrate that the
AP-1 and NF-kB sites of the IL-8 gene are important for cell
line-specific activation of paclitaxel-induced gene expression.
In contrast, the C/EBP site (42), essential for IL-8 induction by
TNF-a, IL-1, and TPA in other cell types, is not involved in this
form of paclitaxel responsiveness.
Paclitaxel activates DNA binding by the AP-1 factor. To
investigate the trans-acting factors that are involved in the
activation of IL-8 by paclitaxel, we performed EMSA using a
probe spanning positions 2130 to 2114 of the IL-8 promoter,
which includes the AP-1 binding site at 2126 to 2120 bp (Fig.
4A). Paclitaxel treatment for 30 min induced strong binding to
this DNA (compare Fig. 4A, lanes 1 and 2) comparable to that
induced by PMA (Fig. 4A, lane 3). This binding was specifically
competed by an excess of wild-type unlabeled AP-1 (Fig. 4A,
lanes 4 to 6) but not by an oligonucleotide containing point
mutations which abolished AP-1 binding (Fig. 4A, lanes 7 to 9).
To determine if the complex contains AP-1, anti-Jun antibody
was used in a supershift assay. The antibody specifically shifted
and diminished this DNA-protein complex, while a control
normal rabbit serum had no effect (Fig. 4A, lanes 10 to 11).
Taken together, the cold competition and supershift assays
indicate that the DNA-protein complex formed is likely AP-1
(Fig. 4A).
Paclitaxel induced DNA-binding by NF-kB but not by C/
EBP. Previous reports have described the cooperative binding
of NF-kB and C/EBP to adjacent binding sites in IL-1-, TNF-
a-, and TPA-stimulated fibrosarcoma cells (42, 53). To deter-
mine whether paclitaxel also induces IL-8 expression through
the synergistic stimulation of NF-kB and C/EBP, EMSA anal-
yses were performed with NF-kB and C/EBP DNA probes.
Incubation of nuclear extracts from paclitaxel-stimulated
OVCA 420 cells with the IL-8 NF-kB probe resulted in in-
FIG. 3. Paclitaxel-induced IL-8 gene expression is specific for the NF-kB
region of the IL-8 gene. (A) The constructs used are diagrammed. Three copies
of the cis-acting elements corresponding to either the NF-kB or the C/EBP site
of the IL-8 gene, two copies of the AP-1 site from the IL-8 gene, three copies of
the NF-kB site from the HLA-B7 gene, and three copies of the AP-1 site from
the collagenase gene were linked to the minimal promoter region of the IL-8
gene, generating the indicated plasmids. (B) Transfection, cytokine treatment,
and CAT assays were performed as described in Materials and Methods. Pacli-
taxel (Taxol) induces CAT or luciferase expression in OVCA 420 cells trans-
fected with pUXCAT 3X(280/271) (left) and pUXLUC 2X(2126/2120)
(right). A positive control for AP-1 activation, PMA, induces luciferase activity
sevenfold more than DMSO. An activated form of MEKK (mu1 MEKK) in-
duces luciferase by 35-fold. (C) Unresponsive OVCA 194 cells did not respond
to paclitaxel with any of the promoter constructs. The results are taken from
three independent experiments.
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creased formation of two DNA-protein complexes. DMSO-
treated OVCA 420 cells gave rise to a faint complex with lower
mobility (Fig. 4B, lane 2). Both complexes were specifically
inhibited by an excess of the unlabeled NF-kB fragment but
not by a mutant NF-kB fragment (Fig. 4B, lanes 3 and 4).
Nuclear extracts from paclitaxel-treated OVCA 420 cells incu-
bated with the C/EBP probe showed no increase in binding
over DMSO-treated extracts (Fig. 4C, lanes 1 and 2). The
complex was specifically competed by the C/EBP probe but not
by the mC/EBP fragment (Fig. 4C, compare lanes 3 and 4).
This indicates that paclitaxel-induced proteins bind the NF-kB
site but not the C/EBP site, which is in agreement with the
functional data shown in Fig. 1 and 3.
To further characterize the kB complex, supershift experi-
ments using specific antisera were performed. The preparation
of nuclear extract for the assay shown in Fig. 4B was not
optimal for supershift analysis, and a modified protocol was
necessary. Nuclear extracts of paclitaxel-treated OVCA 420
cells were first dialyzed in buffer D containing 20 mM HEPES,
20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.5 mM PMSF,
and 0.5 mM DTT and then incubated with binding buffer and
antibodies against the p50 and p65 subunits of human NF-kB
as described in Materials and Methods (Fig. 4D). Antibody
against NF-kB p50 abolished the formation of both complexes
C1 and C2 (Fig. 4D, compare lanes 4 and 2) and resulted in a
faint supershifted band (Fig. 4D). Anti-p65 antibodies also
reduced the C2 complex, blocked formation of the C1 com-
plex, and produced a supershifted band. In a similar experi-
ment performed with antibodies against other members of the
Rel family (e.g., p52) or an unrelated antibody (e.g., Sp1),
supershifted bands were not observed (data not shown). It is
possible that C1 may represent a p50-p65 heterodimer product
and C2 may represent a slightly degraded p50-p65 heterodimer
product. Two other bands appeared only in paclitaxel-treated
cells and were eliminated by anti-p65 antibodies and dimin-
ished by anti-p50 antibodies. They may also be degraded
NF-kB products. It is important to note that paclitaxel did not
induce AP-1 or NF-kB binding in the paclitaxel-nonresponsive
cell line OVCA 194 (data not shown).
Mechanism of paclitaxel activation of AP-1 and NF-kB. To
explore the pathways responsible for paclitaxel activation of
AP-1 and NF-kB, OVCA 420 cells were preincubated for 2 h
with protein kinase inhibitors and agonists prior to treatment
with paclitaxel. The cells were then harvested, and extracts
were prepared for EMSA. Protein kinase C (PKC) inhibitors
(staurosporine and calphostin), tyrosine kinase inhibitor
(genistein), and PKA activator (forskolin) were used. The re-
sults show that preincubation of OVCA 420 cells for 2 h with
10 nM staurosporine nearly abolished the paclitaxel induction
of NF-kB binding activity (Fig. 5A, lane 3). Five nM calphostin
C partially reduced NF-kB binding activity, whereas 25 mM
forskolin or genistein had little effect (Fig. 5A). On the other
hand, preincubation of OVCA 420 cells for 2 h with forskolin
almost completely inhibited paclitaxel-induced AP-1 binding
(Fig. 5B). Calphostin C minimally reduced AP-1 activity, but
genistein had no obvious effect. Lastly, none of these inhibitors
FIG. 4. Gel mobility shift assay. (A) Characterization of nuclear factors binding to the 2130 to 2114 segment of the IL-8 gene. A 32P-labeled DNA fragment was
mixed with 4 mg of nuclear protein extract prepared from OVCA 420 cells stimulated with paclitaxel (T) (30 mM) (lanes 1, 4, 7, 10, and 11), DMSO (D) (lanes 2, 5,
8, and 12), and PMA (P) (1 mg/ml) (lanes 3, 6, and 9) for 30 min in 20 ml of binding reaction buffer in the absence and presence of an unlabeled wild-type (w) DNA
fragment (lanes 4 to 6) and a mutant (m) DNA fragment (lanes 7 to 9). For the supershift study, 1 ml of antibody (Ab), either normal rabbit serum (NRS) (lane 10)
or anti-c-Jun (lanes 11 and 12), was incubated with nuclear extracts and reaction buffer on ice for 1 h prior to the addition of the radiolabeled probe. The arrow indicates
the DNA-protein complexes. (B) A 32P-labeled DNA fragment spanning positions 285 to 264 (280 to 271 in the IL-8 gene contains the NF-kB binding site) was mixed
with nuclear extracts from OVCA 420 cells treated with either paclitaxel (30 mM) (lanes 1, 3, and 4) or DMSO (lane 2) for 30 min in the absence (lanes 1 and 2) or
presence of an unlabeled wild-type DNA fragment (lane 3) and a mutant competitive DNA fragment (lane 4). (C) A 32P-labeled DNA fragment spanning positions
297 to 278 (294 to 281 in the IL-8 gene spans the C/EBP binding site) was mixed with nuclear extracts from OVCA 420 cells treated with either paclitaxel (30 mM)
(lanes 1, 3, and 4) or DMSO (lane 2) for 30 min in the absence (lanes 1 and 2) or presence of an unlabeled competitive wild-type DNA fragment (lane 3) and a mutant
DNA fragment (lane 4). The arrow indicates DNA-protein complexes. (D) Analysis of the components of complexes C1 and C2 by supershift with antibodies directed
against p50 and p65. OVCA 420 cells were treated with either DMSO (lane 1) or paclitaxel (30 mM) (lanes 2 to 4) for 30 min. Nuclear extracts were prepared, and
EMSA was performed with the NF-kB element as the probe in the presence of either anti-p50 or anti-p65 as indicated. Asterisks mark bands that appeared only in
paclitaxel-treated cells which may represent degraded p65 or p50.
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affected C/EBP activity (Fig. 5C). Collectively, these results
suggest that both PKC and PKA can contribute to the pacli-
taxel activation of NF-kB and AP-1, respectively. The differ-
ential effects of these inhibitors on binding by NF-kB, AP-1,
and C/EBP indicate that these inhibitors are not causing a
generalized change in the level or activity of DNA-binding
proteins but rather a factor-specific change.
Effect of kinase inhibitors on IL-8 synthesis. To determine if
the effects of staurosporine and forskolin on transcription fac-
tor binding can be extended to paclitaxel-induced IL-8 cyto-
kine synthesis, Northern blot analysis and ELISA were per-
formed. Staurosporine added for 2 h prior to the addition of
paclitaxel caused a decrease of paclitaxel-induced IL-8 tran-
script. A significant decrease in IL-8 transcript was also ob-
served in forskolin-treated OVCA 420 cells. Genistein mini-
mally influenced IL-8 transcript levels (Fig. 6A). As a control
for loading, the levels of GAPDH were examined and they
were identical. Consistent with the results of Northern blots,
forskolin and staurosporine dramatically reduced paclitaxel-
induced IL-8 cytokine expression as measured by an ELISA
while genistein had a minimal effect on IL-8 expression (Fig.
6B). These results indicate that the effects of these modulators
are manifested at the level of transcription factors, which then
correlate with IL-8 chemokine induction.
DISCUSSION
IL-8 is produced by various human somatic cells, including
monocytes/macrophages, fibroblasts, keratinocytes, mesangial
cells, vascular endothelial cells, and several types of tumor cell
lines. Previously, we found that a promising chemotherapeutic
agent, paclitaxel, transcriptionally induced IL-8 in a subgroup
of ovarian carcinomas (32). This finding has significant thera-
FIG. 5. (A) Role of selected protein kinases in the paclitaxel (Taxol) activation of NF-kB. OVCA 420 cells (5 3 106/sample) were preincubated with staurosporine
(STSN; 10 nM) (lane 3), calphostin (CAL; 5 nM) (lane 4), genistein (GEN; 25 mM) (lane 5), and forskolin (FOR; 25 mM) (lane 6) for 2 h. The cells were stimulated
with paclitaxel (T; 30 mM) for 30 min, and the nuclear extracts were collected. NF-kB binding activity was examined by EMSA with a double-stranded oligonucleotide
probe comprising the NF-kB sequence of the IL-8 promoter. Nuclear extracts from DMSO-treated OVCA 420 cells were used as a control (lane 2). The specificity of
binding was examined by incubation of nuclear extracts with unlabeled wild-type (w) NF-kB oligonucleotide (lane 7). (B) Role of different protein kinases in the
paclitaxel activation of AP-1. The same nuclear extracts as in panel A were incubated with the AP-1 sequence of the IL-8 gene. The specificity of binding was determined
in the presence of unlabeled wild-type AP-1 (lane 6) or mutant (m) AP-1 oligonucleotide (lane 7). (C) Role of different protein kinases in the paclitaxel activation of
C/EBP. A 32P-labeled C/EBP sequence of the IL-8 gene was used as the probe for EMSA analysis. The specificity of binding was assessed by competition with unlabeled
wild-type C/EBP oligonucleotide (lanes 7 and 8). Unlabeled arrows indicate specific DNA-protein complexes.
FIG. 6. Effects of protein kinase inhibitors on IL-8 expression and protein
secretion in OVCA 420 cells pretreated with staurosporine (STSN; 10 nM),
forskolin (FOR; 25 mM), and genistein (GEN; 25 mM) for 2 h and then exposed
to 30 mM paclitaxel (T or Taxol). (A) OVCA 420 cells pretreated with the
indicated pharmacologic agents and then further stimulated with paclitaxel (30
mM) for 4 h. Total RNA (5 mg per lane) was analyzed by Northern analysis. Blots
were probed sequentially for IL-8 and GAPDH. (B) Supernatants were analyzed
for IL-8 protein by ELISA as described in Materials and Methods. Pretreatment
with staurosporine (10 nM) and forskolin (25 mM) blocks paclitaxel-induced IL-8
protein. Results are expressed as the means 6 standard errors of triplicate
experiments.
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peutic implications and provides an important model to eluci-
date the mechanism by which paclitaxel induces gene expres-
sion, which has not been previously elucidated.
Our primary goal is to determine the mechanism by which
paclitaxel activates the IL-8 promoter in human ovarian carci-
nomas. It has been shown that a variety of agents, such as IL-1,
phorbol esters, TNF-a, and the hepatitis B virus X protein, can
activate IL-8 gene expression (34, 42). These analyses reveal
that the sequence from 294 to 271 bp, consisting of C/EBP
and NF-kB binding sites, is required for responsiveness to
these inducers. In contrast to previous reports (42, 53), we now
report that paclitaxel induction of IL-8 is independent of an
intact C/EBP site. Rather, IL-8 gene activation by paclitaxel
appears to be mediated by the AP-1 site in conjunction with
the NF-kB site. The requirement for a similar region for IL-8
transcription by cytokines has been observed in human lung
epithelial cell lines (43) and a human gastric cancer cell line,
MKN 45 (57). These results suggest that different sets of nu-
clear transcription factors may be responsible for the regula-
tion of IL-8 gene transcription in a cell type- and inducer-
specific manner. Interestingly, lung carcinoma, similarly to the
ovarian carcinoma studied here, is clinically responsive to pa-
clitaxel. It will be critical to determine if the molecular utili-
zation of NF-kB and AP-1 by subsets of tumor cells correlates
with a clinical phenotype.
One noteworthy observation is the differential response of
various ovarian carcinomas to paclitaxel treatment. Previously,
we noted that approximately 50% of ovarian carcinoma lines
synthesize IL-8 upon paclitaxel treatment (32). This observa-
tion has been extended to primary freshly explanted ovarian
cancer cells (32). Analysis of ovarian cancer cell lines which
represent each of the two phenotypes discussed in this report
shows that the nonresponsive phenotype exemplified by
OVCA 194 and OVCA 494 cells is correlated with the lack of
IL-8 promoter activation. Further analysis of OVCA 194 cells
traced this to a lack of AP-1 and NF-kB activation by pacli-
taxel. There are at least two possible explanations for the
difference between responsive and nonresponsive cells. It is
possible that nonresponsive cells are deficient in the appropri-
ate signals necessary for the activation of distinct sets of tran-
scription factors. This includes an array of activation cascades
controlling the relevant transcription factors, such as appropri-
ate expression, modification, and cellular localization. In the
case of NF-kB, different IkB inhibitors also have to be consid-
ered. Alternatively, nonresponsive cells may not receive the
signal transmitted upon paclitaxel binding. Elucidating why
some cancer cells respond to paclitaxel and how distinct sets of
transcription factors are involved in IL-8 gene expression in
different types of ovarian cell lines will be important in under-
standing paclitaxel’s mode of action. Correlating this molecu-
lar difference with variations in clinical responsiveness may
provide a molecular explanation for the therapeutic pathways
of paclitaxel.
It has been documented that microtubule-depolymerizing
agents, such as nocodazole and colchicine, can activate several
genes, including IL-1b (19, 35) and urokinase-type plasmino-
gen activators, in specific cells (6, 31). Therefore, we wish to
determine if the effects of paclitaxel on IL-8 genes are related
to its effects on microtubules. A construct composed of three
tandemly repeated copies of the NF-kB element from the IL-8
gene was significantly activated by paclitaxel and much less
activated by colchicine (Fig. 3). An equal activation of this
construct by colchicine was also observed in the nonresponsive
OVCA 194 cells, indicating that the colchicine effect is not cell
restricted. In contrast, the induction of NF-kB by paclitaxel
was only found in the OVCA 420-responsive line.
To further test if the effect of paclitaxel on IL-8 induction is
related to its effect on microtubules, OVCA 420 cells were
treated with colchicine and vinblastine. Neither drug had any
effect on either IL-8 synthesis or NF-kB activation by paclitaxel
(data not shown). Thus, the activation of NF-kB by paclitaxel
may not be solely due to changes in microtubules. We are
aware that colchicine and vinca alkaloids cause microtubule
depolymerization while paclitaxel prevents depolymerization,
although the end result of all three treatments is the disruption
of microtubule function. It is possible that these different
modes of action for colchicine versus paclitaxel may account
for the difference in IL-8 induction. However, paclitaxel pro-
moted microtubule polymerization and disrupted the depoly-
merization of microtubules nearly identically in OVCA 194
cells and OVCA 420 cells, which differ in their IL-8 response
(53a). This dissociates the effects of paclitaxel on IL-8 induc-
tion and microtubules. In addition, our comparison of IL-8
gene induction and cytotoxicity in OVCA 420 cells by using 12
structurally related paclitaxel analogs (54) revealed 3 analogs
that induced IL-8 synthesis in the ovarian lines, but tubulin
stabilization was observed for all 12 analogs. Recent studies of
murine macrophages indicate that the effects of paclitaxel on
TNF-a gene expression or nitric oxide (NO) production are
distinct from its well-known effects on microtubules (7, 27, 37,
38). Structure-activity relationship studies show that changes in
the structure of paclitaxel do not alter cytotoxicity but prevent
TNF-a gene expression (7, 27). Furthermore, docetaxel (Taxo-
tere), a semisynthetic taxoid which is more potent than pacli-
taxel as an inducer of microtubule bundling, did not induce
TNF-a gene activation and production (38). These composite
results strongly suggest that paclitaxel may have an additional
antitumor effect in addition to its effects on microtubules.
This study also suggests that paclitaxel-induced activation of
IL-8 expression in human ovarian cells is associated with the
intracellular signaling pathway. This conclusion is supported by
the following observations. The addition of specific kinase in-
hibitors or adenyl cyclase activators inhibited paclitaxel-in-
duced NF-kB and AP-1 binding to cognate DNA, respectively,
and caused a correlative diminution of IL-8 gene expression.
Although the signaling pathway leading to NF-kB activation is
still not entirely understood, a report by Perera et al. showed
that paclitaxel could induce the translocation of NF-kB to the
nucleus of murine macrophages in a manner mimicking LPS
(48). Several kinases have been proposed in the activation of
NF-kB, including the double-stranded-RNA-activated kinase
(PKR), which phosphorylates IkBa in vitro (28); Raf-1, which
targets IkBa (33), leading to the activation of gene expression
through a kB site (20); and PKC z subspecies, which acts as a
regulator of NF-kB (4, 12, 16). Finally, many different inducers
of NF-kB, such as ultraviolet light, LPS, and proinflammatory
cytokines, may affect the stress-activated protein kinases or
their regulators, and these kinases may also play a role in IkB
phosphorylation (2). It will be of interest to test if paclitaxel
affects any of these kinases.
The downregulation of AP-1 activity by forskolin is consis-
tent with several earlier observations showing cross-talk be-
tween the cyclic AMP (cAMP) and AP-1 (3, 11, 26, 58). The
AP-1 transcription factor binds to 12-O-tetradecanoylphorbol-
13-acetate-responsive element (TRE) palindromic sequences.
TREs are similar to cAMP-responsive elements (CREs), and
Jun and Fos are structurally similar to CRE-binding proteins
(CREBs), which employ cAMP as a second messenger. Thus,
the two main signal transduction pathways have closely related
nuclear effectors which could possibly cross talk. CRE modu-
lator proteins and CREBs can bind to a TRE and therefore
compete with Jun for binding (39). Forskolin, which activates
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the CREs by increasing intracellular cAMP levels, has been
shown to inhibit AP-1 activity and to revert AP-1-dependent
transformation (17, 18). The molecular mechanism by which
forskolin inhibits AP-1 may involve interaction between
CREBs and Jun protein, thereby inhibiting basal and induced
AP-1 activity (39). It is likely that forskolin inhibits paclitaxel-
induced IL-8 in ovarian carcinoma cells by similarly modulat-
ing AP-1 activity.
We have previously investigated proinflammatory cytokine
expression in a series of cell lines and recent explants of human
ovarian cancer cells (32), and we have found that paclitaxel
induced secretion of IL-8, but not IL-6, IL-1a, or IL-1b, in a
subgroup of human ovarian cancer cell lines; thus, this effect is
cytokine specific. Paclitaxel did not induce IL-8 in breast car-
cinoma, endometrial stromal, or T-lymphocyte or human pri-
mary monocyte cultures, revealing another aspect (cell speci-
ficity) of this phenomenon. Furthermore, a recent report from
our group noted that paclitaxel alone enhanced IL-1b mRNA
levels and secretion in human primary monocytes as long as
the cells were cultured in the more physiologically autologous
human serum but not in fetal calf serum (55). All these studies
indicate a complicated web of gene regulation that is signifi-
cantly altered by paclitaxel, and the composite effects may
determine the outcome of patient responsiveness to the che-
motherapy.
In summary, this report shows that paclitaxel induces the
NF-kB and AP-1 transcription factors, which in turn upregu-
late the IL-8 gene in a subgroup of human ovarian cancer cell
lines. From a broader perspective, the activation of AP-1 and
NF-kB most likely affects the expression of myriad target
genes. Identifying these genes and understanding their role in
tumor growth or inhibition will be crucial in understanding the
antitumor mechanism of paclitaxel. From a biological stand-
point, IL-8 may be produced locally by paclitaxel-treated ovar-
ian cancer cells and lead to the infiltration of T lymphocytes
and neutrophils into tumor sites. Such a mechanism would
suggest that leukocyte infiltration induced by IL-8 in human
ovarian cells may play a role in initiating immune responses to
tumor cells or may control tumor cell growth and metastasis
(21, 51). A recent report from one of our groups shows that the
introduction of IL-8 into hamster ovarian tumor cells reduced
tumorigenicity in nude mice in association with neutrophilic
infiltration (23). The role of IL-8 in human ovarian cancer cell
growth in nude mice is currently being investigated. On the
other hand, IL-8 also promotes angiogenesis, where it is pos-
sible that IL-8 induction by paclitaxel may have differential
effects on the growth of primary tumors and the spreading of
secondary growth. Regardless of which scenario takes place,
this induction is likely to have significant clinical implications.
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